Literature DB >> 16634961

RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.

Naoya Asai1, Mayumi Jijiwa, Atsushi Enomoto, Kumi Kawai, Kengo Maeda, Masatoshi Ichiahara, Yoshiki Murakumo, Masahide Takahashi.   

Abstract

Gain-of-function mutations within the receptor tyrosine kinase gene RET cause inherited and non-inherited thyroid cancer. Somatic gene rearrangements of RET have been found in papillary thyroid carcinoma and germline point mutations in multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid carcinoma (FMTC). Conversely, loss-of-function mutations are responsible for the development of Hirschsprung's disease, a congenital malformation of the enteric nervous system. Comparison between normal RET signaling activated by the RET ligand glial cell line-derived neurotrophic factor (GDNF) and abnormal RET signaling caused by various mutations has led to a deeper understanding of disease mechanisms. The focus of the present review is on recent progress in the study of RET signaling dysfunction in human diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634961     DOI: 10.1111/j.1440-1827.2006.01942.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  19 in total

1.  Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.

Authors:  Matthew J Smith; W Rod Hardy; James M Murphy; Nina Jones; Tony Pawson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

2.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Ya'an Kang; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  Cell type specificity of signaling: view from membrane receptors distribution and their downstream transduction networks.

Authors:  Ying He; Zhonghao Yu; Dongya Ge; Rui Wang-Sattler; Hans-Jürgen Thiesen; Lu Xie; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

Review 5.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

6.  Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.

Authors:  Brittany Bohinc; Gregory Michelotti; Anna Mae Diehl
Journal:  Thyroid       Date:  2013-09       Impact factor: 6.568

Review 7.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

8.  Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.

Authors:  Nadiya Sosonkina; Seung-Keun Hong; Dmytro Starenki; Jong-In Park
Journal:  Genes Genomics       Date:  2014-12       Impact factor: 1.839

9.  Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung's disease.

Authors:  Maria Cecília M Coelho; Uenis Tannuri; Israel Benditt; Maria Merces Santos
Journal:  Pediatr Surg Int       Date:  2008-07-30       Impact factor: 1.827

10.  Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.

Authors:  Noriko Uetani; Kristen Bertozzi; Melanie J Chagnon; Wiljan Hendriks; Michel L Tremblay; Maxime Bouchard
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.